Who is sponsoring NCT06204770?

NCT06204770 is sponsored by Danone Specialized Nutrition Indonesia.

What drugs are being tested in NCT06204770?

Interventions in NCT06204770: extensive hydrolyzed protein formula.

What condition does NCT06204770 study?

NCT06204770 studies Mild to Moderate Cows' Milk Protein Allergy.

Is NCT06204770 still recruiting?

NCT06204770 is currently terminated. Last updated 1 April 2025.

Last reviewed 2025-04-01 · How we verify

NCT06204770: PEACE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tolerance of Extensive Hydrolyzed Whey Protein Milk Among Infant With Mild to Moderate CMPA

Terminated Phase 4 Last updated 1 April 2025

What this trial tests

Phase 4 trial testing extensive hydrolyzed protein formula in Mild to Moderate Cows' Milk Protein Allergy in 15 participants. Terminated before completion.

Timeline

14 July 2023

Primary endpoint
17 January 2024

31 January 2024

Quick facts

Lead sponsor	Danone Specialized Nutrition Indonesia
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	15
Start date	14 July 2023
Primary completion	17 January 2024
Estimated completion	31 January 2024
Sites	5 locations across Indonesia

Drugs / interventions tested

extensive hydrolyzed protein formula

Conditions studied

Mild to Moderate Cows' Milk Protein Allergy — all drugs for Mild to Moderate Cows' Milk Protein Allergy →

Sponsor

Danone Specialized Nutrition Indonesia

Who can join

Adults 3 Months to 11 Months, any sex, with Mild to Moderate Cows' Milk Protein Allergy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to evaluate the tolerance, safety and efficacy of Nutribaby Royal Pepti Junior (NR Pepti) among infants with mild to moderate Cow's Milk Protein Allergy (CMPA). The main questions it aims to answer are: 1. Is NR Pepti tolerable among infants with mild to moderate CMPA? 2. Is NR Pepti safe and effective among infants with mild to moderate CMPA? Participants will be asked to use NR Pepti as part their management of mild to moderate CMPA

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Danone Specialized Nutrition Indonesia trials

Trials by the same sponsor.

NCT05489094 — The Impact of Nutrition Education and Milk Provision in Fueling the Progress of 1 - 3 Years Old Children · Phase 4 · unknown
NCT05393934 — Growth Faltering Intervention Using Pediatric Nutritional Care (PNC) vs.PNC& FSMP · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06204770 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Danone Specialized Nutrition Indonesia
Last refreshed: 1 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06204770.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing